Clinical Trial Update: A Study of LY2127399 in Participants With Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial of LY2127399 in systemic lupus erythematosus has completed enrollment and posted results. The sponsor is Eli Lilly and Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• LY2127399 (dacetuzumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Systemic Lupus Erythematosus, Connective Tissue Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-06-12